Since Opdivo (Nivolumab Injection, commonly known as O Drug) was approved in Japan on July 4, 2014 to become the world’s first PD-1 inhibitor approved by a regulator, it has started its unbelievable road, and has so far been approved 17 indications by the FDA, involving lung cancer (non-small cell lung cancer (NSCLC) and small cell lung cancer), melanoma, renal cell carcinoma, Hodgkin's lymphoma, head and neck squamous cell carcinoma, bladder cancer, colorectal cancer, liver cancer, and gastric cancer, to become the PD-1 inhibitor with the most indications approved.
